HilleVax is a biopharmaceutical company focused on the development and commercialization of novel vaccine candidates. Its initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/08/21 | $135,000,000 | Crossover Financing |
Abingworth BVF Partners Catalys Pacific Deerfield Management Company, L.P. Franklin Templeton Frazier Healthcare Partners  Perceptive Advisors Qiming Venture Partners RA Capital Management Samsara BioCapital | undisclosed |
